245 Main St
3 articles with Immuneering
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
Financing to support advancement of Immuneering’s lead drug programs targeting cancers driven by alterations in the RAS/MAPK pathway and pipeline development of earlier programs in neuroscience and immuno-oncology
Ben Zeskind, chief executive officer of Immuneering, spoke with BioSpace following the annual J.P. Morgan Healthcare conference in San Francisco.